Congress news from FiercePharma
News
The FDA's surprising plea for cash
Finally, FDA chief Andrew von Eschenbach is crying uncle. After weeks of pressure from Congress to request more money for the agency--and weeks of Read more...
Could Clarinex be vulnerable to generics?
Consider this scenario from Fred Hassan's nightmares: The $800 million Clarinex, ostensibly under patent till 2020, Read more...
SPOTLIGHT: AstraZeneca wants FDA ad review
AstraZeneca is lobbying Congress for FDA review of television ads. Last fall lawmakers created a program that would require up-front scrutiny of DTC ads, but didn't give the FDA authority to collect Read more...
Pharma drags feet on promised studies
We once saw a sign in a newsroom that said, "Deadlines, schmedlines, as long as I get paid." Maybe Big Pharma has similar signage posted at its various HQs. According to newly released FDA Read more...
Bill to propose federal drug comparisons
Should the feds fund studies to compare drugs' effectiveness? The idea appears to be gaining traction. Two congressmen are readying legislation that would create an institute to systematically Read more...
Get more Congress coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight